Top

Published in:

01-04-2009 | Review

Pharmacotherapy of urinary incontinence

Authors: Anastasios Athanasopoulos, Petros Perimenis

Published in: International Urogynecology Journal | Issue 4/2009

Abstract

The pathophysiology of urinary incontinence (UI) involves an overactive detrusor (DOA) or an incompetent urethral sphincter. Therefore, the three most common types of UI are stress urinary incontinence (SUI), urge urinary incontinence (UUI), or a combination of stress and urge known as mixed urinary incontinence (MUI). Pharmacotherapy represents a recognized option for the treatment of different types of UI. A literature search of Medline publications on pharmacological treatment of urinary incontinence until 2008 was performed. Relevant data from recently published literature were included. Anticholinergics are the cornerstone of UUI treatment, whereas serotonin and norepinephrine re-uptake inhibitors represent an option for SUI treatment. A significant percentage of patients with UI, mainly those with UUI and MUI, can be treated successfully with pharmacotherapy.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) Standardisation Sub-committee of the International Continence Society. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the international Continence society. Neurourol Urodyn 21:167–178PubMedCrossRef

Thomas TM, Plymat KR, Blannin J, Meade TW (1980) Prevalence of urinary incontinence. Br Med J 281(6250):1243–1245PubMed

Hannestad YS, Rortveit G, Sandvik H, Hunskaar S (2000) Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidem 53(11):1150–1157CrossRef

Milsom I (2006) Epidemiology of stress, urgency, and mixed incontinence: where do the boundaries cross? Eur Urol Suppl 5(16):842–848CrossRef

Herzog AR, Fultz NH (1990) Prevalence and incidence of urinary incontinence in community-dwelling populations. J Am Geriatr Soc 38:273–278PubMed

Schoulman C, Claesm H, Mattijs J (1997) Urinary incontinence in Belgium: a population-based epidemiological survey. Eur Urol 32:315–320

Urt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D (1995) Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 25(3):305–313

Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes. Diabetes Care 27:1047–1053PubMedCrossRef

Silverstein B (1999) Gender difference in the prevalence of clinical depression: the role played by depression associated with somatic symptoms. Am J Psychiatry 156:480–482PubMed

10.

Odeyemi IA, Dakin HA, O'Donnell RA, Warner J, Jacobs A, Dasgupta P (2006) Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. Int J Clin Pract 60(8):949–958PubMedCrossRef

11.

Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T (2004) Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 63(3):461–465PubMedCrossRef

12.

Debruyne FMJ, Heesakkers JPFA (2004) Clinical and socioeconomic relevance of overactive bladder. Urology 63:42–44PubMedCrossRef

13.

Darkow T, Fontes CL, Williamson TE (2005) Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 25:511–519PubMedCrossRef

14.

Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallet D (2005) Employees with overactive bladder: work loss burden. J Occup Environ Med 47:439–446PubMedCrossRef

15.

Morris V, Wagg A (2007) Lower urinary tract symptoms, incontinence and falls in elderly people: time for an intervention study. Int J Clin Pract 61(2):320–323PubMedCrossRef

16.

Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ (2003) Prevalence and burden of overactive bladder in the United States. World J Urology 20(6):327–336

17.

Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 87(9):760–766 Erratum in: Br J Urol Int 88(7):807

18.

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315PubMedCrossRef

19.

Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101(11):1388–1395PubMedCrossRef

20.

Jackson S (1997) The patient with an overactive bladder—symptoms and quality-of-life issues. Urology 50(6A Suppl):18–22PubMedCrossRef

21.

Chapple C (2006) Classification of mixed incontinence. Eur Urol Supp 5(16):837–841CrossRef

22.

Chu FM, Dmochowski R (2006) Pathophysiology of overactive bladder. AJM 119(3A):3S–8SCrossRef

23.

Ouslander JG (2004) Management of overactive bladder. N Engl J Med 350:786–799PubMedCrossRef

24.

Steers DS (2002) Pathophysiology of overactive bladder and urinary incontinence. Rev Urol 4(suppl 4):S7–S18PubMed

25.

Andersson KE (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurology 3(1):46–53PubMedCrossRef

26.

Wefer J, Truss MC, Jonas U (2001) Tolterodine: an overview. World J Urol 19(5):312–318PubMedCrossRef

27.

Robinson D, Cardozo L (2004) The emerging role of solifenacin in the treatment of overactive bladder. Expert Opin Investig Drugs 13(10):1339–1348PubMedCrossRef

28.

Chapple CR (2004) Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs 13(11):1493–1500PubMedCrossRef

29.

Hofner K, Oelke M, Machtens S, Grunewald V (2001) Trospium chloride—an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urology 19(5):336–343CrossRef

30.

Andersson KE, Chapple CR (2001) Oxybutynin and the overactive bladder. World J Urology 19(5):319–323CrossRef

31.

De Wachter S, Wyndaele JJ (2003) Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol 169(5):1892–1895PubMedCrossRef

32.

Madersbacher H, Murtz G (2001) Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urology 19(5):324–335CrossRef

33.

Herbison P, Hay-Smith J, Ellis G, Moore K (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 326(7394):841–844CrossRef

34.

Chapple C, Khullar V, Gabriel Z, Dooley JA (2005) The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48(1):5–26PubMedCrossRef

35.

Haab F, Castro-Diaz D (2005) Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 59(8):931–937PubMedCrossRef

36.

Kirby M, Artibani W, Cardozo L, Chapple C, Diaz DC, De Ridder D, Espuna-Pons M, Haab F, Kelleher C, Milsom I, Van Kerrebroeck P, Vierhout M, Wagg A (2006) Overactive bladder: the importance of new guidance. Int J Clin Pract 60(10):1263–1271PubMedCrossRef

37.

Abrams P, Freeman R, Anderstrom C, Mattiasson A (1998) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81(6):801–810PubMed

38.

Giannitsas K, Perimenis P, Athanasopoulos A, Gyftopoulos K, Nikiforidis G, Barbalias G (2004) Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. Eur Urol 46(6):776–782PubMedCrossRef

39.

Abrams P, Swift S (2005) Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol 48(3):483–487PubMed

40.

Novara G, Galfano A, Secco S, D’Elia C, Cavalleri S, Ficarra V, Artibani W (2008) A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 54:740–764PubMedCrossRef

41.

Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner KA (1999) Placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. Br J Urol International 84(6):646–651

42.

Junemann KP, Halaska M, Rittstein T, Murtz G, Schnabel F, Brunjes R, Nurkiewicz W (2005) Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol 48(3):478–482PubMed

43.

Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J, for the STAR study group (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48(3):464–470PubMed

44.

Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, Mistry A, Wright DM, Bolodeoku J, STAR study group (2007) Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 52(4):1195–1203PubMedCrossRef

45.

Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S, Trospium Study Group (2004) Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171(6):2311–2315PubMedCrossRef

46.

Junemann KP, Al-Shukri S (2000) Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double blind, placebo controlled multicenter clinical trial. Neurourl Urodyn 19:488–493

47.

Nitti V, Wiatrak M, Kreitman L, Lipsitz D (2005) Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB)Q results of a phase 2 trial. Paper presented at International Continence Society Montreal, Canada, August 31–September 2

48.

Chaple C, Kerrebrock PV, Tubaro A, Haag-Molkenteller c, Forst HT, Massow U, Wang J, Brodsky M (2007) Clinical efficacy, safety, and tolerability of once—daily fesoterodine in subjects with overactive bladder. Eur Urol 52(4):1204–1212CrossRef

49.

Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P, Davis BE (1999) Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 161(5):1551–1555PubMedCrossRef

50.

Yarker YE, Goa KL, Fitton A (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6(3):243–262PubMed

51.

Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54(3):543–562PubMedCrossRef

52.

Athanasopoulos A, Perimenis P (2005) Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Exp Opin Pharmac 6(14):2429–2433CrossRef

53.

Hunsballe JM, Djurhuus JC (2001) Clinical options for imipramine in the management of urinary incontinence. Urol Res 29(2):118–125PubMedCrossRef

54.

Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J (2002) Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 89(9):855–862PubMedCrossRef

55.

Lose G, Lalos O, Freeman RM, van Kerrebroeck P, Nocturia Study Group (2003) Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 189(4):1106–1113PubMedCrossRef

56.

Robinson D, Cardozo L, Akeson M, Hvistendahl G, Riis A, Norgaard JP (2004) Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int 93(7):996–1000PubMedCrossRef

57.

Park JT, Song C, Choo M (2002) The effect of bladder training, tolterodine and bladder training with tolterodine in female patients with overactive bladder: a prospective randomized study. Neurol Urodyn 21:434–438

58.

Song C, Park JT, Heo KO, Lee KS, Choo MS (2006) Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci 21(6):1060–1063PubMedCrossRef

59.

Viktrup L (2002) Female stress and urge incontinence in family practice: insight into the lower urinary tract. Int J Clin Pract 56(9):694–700PubMed

60.

Cardozo L (2004) New developments in the management of stress urinary incontinence. Br J Urol Int 94(suppl 1):1–3

61.

Pesce F (2004) Current management of stress urinary incontinence. Br J Urol Int 94(suppl 1):8–13

62.

Viktrup L, Bump RC (2003) Pharmacological agents used for the treatment of stress urinary incontinence in women. Curr Med Res Opin 19(6):485–490PubMedCrossRef

63.

Nasu K, Moriyama N, Fukasawa R, Tsujimoto G, Tanaka T, Yano J, Kawabe K (1998) Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol 123(7):1289–1293PubMedCrossRef

64.

Andersson KE, Appell R, Cardozo LD, Chapple C, Drutz HP, Finkbeiner AE, Haab F, Vela Navarrete R (1999) The pharmacological treatment of urinary incontinence. Br J Urol Int 84(9):923–947

65.

Alhasso A, Glazener CM, Pickard R, N'Dow J (2003) Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev 2:CD001842PubMed

66.

Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI (2000) Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 343(25):1826–1832PubMedCrossRef

67.

Fleming GA (2000) The FDA, regulation, and the risk of stroke. N Engl J Med 343(25):1886–1887PubMedCrossRef

68.

Hextall A (2000) Oestrogens and lower urinary tract function. Maturitas 36(2):83–92PubMedCrossRef

69.

Grady D, Brown JS, Vittinghoff E (2001) Postmenopausal hormones and incontinence: the Heart and Estrogen? Progestin Replacement study. Obst Gynecol 97:116–120CrossRef

70.

Grodstein F, Lifford K, Resnick NM (2004) Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 103:254–260PubMed

71.

Michel MC, Petes SLM (2004) Role of serotonin and noradrenaline in stress urinary incontinence. Br J Urol Int 94(suppl 1):23–30

72.

Thor KB, Katofiasc MA (1995) Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharm Exp Ther 274(2):1014–1024

73.

Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC (2003) Duloxetine urinary incontinence study group. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 170:1259–1263 Erratum in: J Urol (2004); 171(1):360PubMedCrossRef

74.

Kerrebroeck PV (2004) Duloxetin: an innovative approach for treating stress urinary incontinence. Br J Urol International 94(suppl 1):31–37

75.

Thor KB, Kirby M, Viktrup L (2007) Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract 61(8):1349–1355PubMedCrossRef

76.

Norton PA, Zinner NR, Yalcin I, Bump RC (2002) Duloxetine urinary incontinence study group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstetr Gyn 187(1):40–48CrossRef

77.

Ghoniem GM, Van Leeuwen JS, Elser DM, Freeman RM, Zhao YD, Yalcin I, Bump RC (2005) Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173(5):1647–1653PubMedCrossRef

78.

Mariappan P, Alhasso A, Ballantyne Z, Grant A, N’Dow J (2007) Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol 51:67–74PubMedCrossRef

79.

Castro-Diaz D, Palma PC, Bouchard C, Haab F, Hampel C, Carone R, Zepeda Contreras S, Rodriguez Ginorio H, Voss S, Yalcin I, Bump RC (2007) Duloxetine dose escalation study group. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 18(8):919–929PubMedCrossRef

80.

Cardozo L (2006) Pharmacotherapy in stress and mixed incontinence. Eur Urol Suppl 5:854–859CrossRef

81.

Khullar V, Hill S, Laval KU, Schiøtz HA, Jonas U, Versi E (2004) Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 64:269–274PubMedCrossRef

82.

Smith KE, McGuire E (2008) Mixed urinary incontinence. In: Raz S, Rodriguez LV (eds) Female urology. 3rd edn. Elsevier, Philadelphia, pp 477–485

83.

Andersson KE, Chapple C, et al (2008) Drug treatment committee. 4th ICI Paris

Title: Pharmacotherapy of urinary incontinence
Authors: Anastasios Athanasopoulos
Petros Perimenis
Publication date: 01-04-2009
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 4/2009
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-008-0761-1

ACC 2024 Congress

Springer Medicine

Pharmacotherapy of urinary incontinence

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

Women with SUI demonstrate motor control differences during voluntary pelvic floor muscle contractions

Experimental comparison of abdominal wall repair using different methods of enhancement by small intestinal submucosa graft

Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months

Changes in connective tissue in patients with pelvic organ prolapse—a review of the current literature

Urogynaecology training in the UK: past, present and future

Female sexual function following surgery for stress urinary incontinence: tension-free vaginal versus transobturator tape procedure